Carcinoma, Neuroendocrine Clinical Trials

18 clinical trials for Carcinoma, Neuroendocrine across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity — RECRUITING · PHASE2
• A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors — RECRUITING · PHASE1
• Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) — RECRUITING
• A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours — SUSPENDED · PHASE2
• Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) — COMPLETED
• Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) — NOT_YET_RECRUITING · PHASE2
• Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors — COMPLETED · PHASE1
• Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers — COMPLETED · PHASE1
• Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs — WITHDRAWN
• Personalized PRRT of Neuroendocrine Tumors — ACTIVE_NOT_RECRUITING · PHASE2
• Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types — COMPLETED · PHASE2
• Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s — TERMINATED
• An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis — COMPLETED · PHASE1
• TheraSphere for the Treatment of Liver Metastases — COMPLETED · PHASE2
• Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery — TERMINATED · PHASE2
• KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors — COMPLETED · PHASE2
• A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers — COMPLETED · PHASE1
• Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract — COMPLETED · PHASE2

Refine this search